Tiziana Life Sciences disclosed positive PET imaging results from the third patient in its Phase 2 MSA trial of intranasal foralumab, with significant neuroinflammation reductions (up to 34% SUV and 26% SUVR). Results echo the first two patients, bolstering the treatment’s inflammatory-modulation potential. The next catalyst is MS topline data due by late Q3/early Q4 2026, while the stock reacted modestly higher.
Recent results from Tiziana Life Sciences highlight their nasal anti-CD3 therapy's promise in reversing cognitive decline, supporting ongoing clinical trials for conditions such as Alzheimer's and Multiple Sclerosis. The stock has shown a recent uptick, but technical indicators suggest mixed momentum, indicating caution for investors while key resistance and support levels are outlined.
- TLSA approved by FDA to expand patient enrollment for na-SPMS program to 30 patients. Price Impact Rating: Bullish Impact Horizon Rating: Short-term Type: Corporate Developments
- Tiziana Life Sciences received a notice from Nasdaq stating they are not in compliance with the $1.00 Minimum Bid Price Requirement. - The company has 180 days to regain compliance by having the closing bid price reach or exceed $1.00 for at least ten consecutive days. - The notice does not currently impact the listing or trading of the company's securities. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Corporate Developments
